A patient with a large recurrent pheochromocytoma demonstrating the pitfalls of diagnosis

Nature Reviews Endocrinology

Volumn 7, Issue 12, 2011, Pages 749-755

  Singer, Jörg ^a   Koch, Christian A ^b   Kassahun, Woubet ^a   Lamesch, Peter ^c   Eisenhofer, Graeme ^d   Kluge, Regine ^a   Lincke, Thomas ^a   Seiwerts, Matthias ^a   Borte, Gudrun ^a   Schierle, Katrin ^a   Paschke, Ralf ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c Klinikum St Georg   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 6 FLUORODOPA F 18; ADRENALIN; CHROMOGRANIN A; ENALAPRIL; GLIMEPIRIDE; METOPROLOL; NITRENDIPINE; NORADRENALIN; PHENOXYBENZAMINE; ROSIGLITAZONE; SYNAPTOPHYSIN;

ABDOMINAL PAIN; ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HYPERTENSION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PEROPERATIVE ECHOGRAPHY; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR RECURRENCE;

ABDOMINAL PAIN; ADRENAL GLAND NEOPLASMS; ANTIHYPERTENSIVE AGENTS; CHROMOGRANIN A; DIABETES MELLITUS, TYPE 2; EPINEPHRINE; HUMANS; HYPERTENSION; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; METANEPHRINE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NOREPINEPHRINE; NORMETANEPHRINE; PHEOCHROMOCYTOMA; SYNAPTOPHYSIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENA CAVA, INFERIOR;

EID: 82155185163     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.132     Document Type: Article

References (30)

1. Lenders, J. W., Eisenhofer, G., Mannelli, M. & Pacak, K. Phaeochromocytoma. Lancet 366, 665-675 (2005).
2. Thompson, L. D. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am. J. Surg. Pathol. 26, 551-566 (2002).
3. Eisenhofer, G. et al. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin. Chem. 51, 735-744 (2005).
4. Eisenhofer, G. et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J. Clin. Endocrinol. Metab. 88, 2656-2666 (2003).
5. Thouënnon, E. et al. Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy. J. Clin. Endocrinol. Metab. 92, 4865-4872 (2007).
6. Sawka, A. M. et al. A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma. BMC Endocr. Disord. 4, 2 (2004).
7. Pacak, K. et al. A "pheo" lurks: novel approaches for locating occult pheochromocytoma. J. Clin. Endocrinol. Metab. 86, 3641-3646 (2001).
8. Peaston, R. T., Graham, K. S., Chambers, E., van der Molen, J. C. & Ball, S. Performance of plasma free metanephrines measured by liquid chromatography-tandem mass spectrometry in the diagnosis of pheochromocytoma. Clin. Chim. Acta 411, 546-552 (2010).
9. Unger, N. et al. Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur. J. Endocrinol. 154, 409-417 (2006).
10. Pillai, D. & Callen, S. Pilot quality assurance programme for plasma metanephrines. Ann. Clin. Biochem. 47 (Pt 2), 137-142 (2010).
11. Algeciras-Schimnich, A., Preissner, C. M., Young, W. F. Jr, Singh, R. J. & Grebe, S. K. Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J. Clin. Endocrinol. Metab. 93, 91-95 (2008).
12. Qin, Y., Buddavarapu, K. & Dahia, P. L. Pheochromocytomas: from genetic diversity to new paradigms. Horm. Metab. Res. 41, 664-671 (2009).
13. Majumdar, S. et al. Compound heterozygous mutation with a novel splice donor region DNA sequence variant in the succinate dehydrogenase subunit B gene in malignant paraganglioma. Pediatr. Blood Cancer 54, 473-475 (2010).
14. Bausch, B., Borozdin, W. & Neumann, H. P. Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N. Engl. J. Med. 354, 2729-2731 (2006).
15. Ricketts, C. J. et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum. Mutat. 31, 41-51 (2010).
16. Lloyd, R. V. Adrenal cortical tumors, pheochromocytomas and paragangliomas. Mod. Pathol. 24 (Suppl. 2), S58-S65 (2011).
17. Morimoto, R. et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr. J. 55, 49-55 (2008).
18. Fiebrich, H. B. et al. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with 123I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J. Clin. Endocrinol. Metab. 94, 3922-3930 (2009).
19. Bhatia, K. S. et al. Reznek RH. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin. Endocrinol. (Oxf.) 69, 181-188 (2008).
20. Jacobson, A. F., Deng, H., Lombard, J., Lessig, H. J. & Black, R. R. 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J. Clin. Endocrinol. Metab. 95, 2596-2606 (2010).
21. Timmers, H. J. et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J. Clin. Endocrinol. Metab. 94, 4757-4767 (2009).
22. Havekes, B. et al. New imaging approaches to phaeochromocytomas and paragangliomas. Clin. Endocrinol. (Oxf.) 72, 137-145 (2010).
23. Huang, H. et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 113, 2020-2028 (2008).
24. Amar, L. et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J. Clin. Endocrinol. Metab. 92, 3822-3828 (2007).
25. Gao, B. et al. Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas. Urology 68, 282-286 (2006).
26. Gao, B. et al. A logistic regression model for predicting malignant pheochromocytomas. J. Cancer Res. Clin. Oncol. 134, 631-634 (2008).
27. Shen, W. T., Sturgeon, C., Clark, O. H., Duh, Q. Y. & Kebebew, E. Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. Surgery 136, 1129-1137 (2004).
28. Strong, V. E. et al. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 143, 759-768 (2008).
29. Pohlink, C. et al. Does tumor heterogeneity limit the use of the Weiss criteria in the evaluation of adrenocortical tumors? J. Endocrinol. Invest. 27, 565-569 (2004).
30. Wilhelm, S. M., Prinz, R. A., Barbu, A. M., Onders, R. P. & Solorzano, C. C. Analysis of large versus small pheochromocytomas: operative approaches and patient outcomes. Surgery 140, 553-559; discussion 559-60 (2006).